Nurix Therapeutics (NRIX) Financials: History & Chart

Nurix Therapeutics, Inc.(NRIX)

Biotechnology · Brisbane, CA

$22.59-0.29 (-1.28%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Brisbane, CA

317 employees

www.nurixtx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur T. Sands

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended May 2026	Quarter ended Feb 2026	Quarter ended Nov 2025	Quarter ended Aug 2025	Quarter ended May 2025	Quarter ended Feb 2025	Quarter ended Nov 2024	Quarter ended Aug 2024
Revenue	36.77M	9.04M	6.25M	13.58M	7.89M	44.06M	18.45M	13.28M	12.59M
Cost of Goods Sold	97.62M	3.85M	84.14M	4.63M	5.00M	78.10M	69.66M	67.22M	55.48M
Gross Profit	-60.85M	5.19M	-77.89M	8.95M	2.89M	-34.04M	-51.21M	-53.94M	-42.89M
Gross Profit Margin	-165.5%	57.4%	-1245.8%	65.9%	36.7%	-77.3%	-277.5%	-406.1%	-340.7%
Total Operating Expenses	300.33M	99.40M	14.61M	92.04M	94.28M	14.28M	11.65M	10.72M	11.72M
Research & Development	338.81M	87.65M	84.14M	80.90M	86.12M	78.10M	69.66M	67.22M	55.48M
Selling, General & Administrative	57.01M	15.59M	14.61M	13.65M	13.16M	14.28M	11.65M	10.72M	11.72M
Operating Income (EBIT)	-361.18M	-94.20M	-92.50M	-83.09M	-91.39M	-48.32M	-62.86M	-64.66M	-54.61M
Operating Margin	-982.4%	-1041.7%	-1479.4%	-612.0%	-1157.7%	-109.7%	-340.7%	-486.7%	-433.8%
Income Before Tax (EBT)	-341.62M	-89.81M	-87.17M	-78.22M	-86.42M	-42.70M	-56.35M	-58.54M	-48.87M
Interest Income	19.56M	4.40M	5.32M	4.87M	4.96M	5.62M	6.51M	6.12M	5.74M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	19.56M	4.40M	5.32M	4.87M	4.96M	5.62M	6.51M	6.12M	5.74M
Net Income	-341.35M	-89.53M	-87.17M	-78.22M	-86.42M	-43.46M	-56.35M	-58.55M	-48.96M
Income Tax Expense	-271K	-271K	0.00	0.00	0.00	760K	0.00	8K	82K
Net Profit Margin	-928.4%	-990.1%	-1394.3%	-576.1%	-1094.8%	-98.7%	-305.4%	-440.7%	-388.9%
EBITDA	-339.29M	-90.35M	-88.72M	-73.83M	-86.39M	-46.08M	-60.51M	-63.41M	-52.22M
EBITDA Margin	-922.8%	-999.2%	-1419.0%	-543.8%	-1094.3%	-104.6%	-327.9%	-477.3%	-414.8%
Depreciation & Amortization	21.89M	3.85M	3.78M	9.26M	5.00M	2.24M	2.35M	1.25M	2.39M
EPS Basic	-3.45	-0.81	-0.79	-0.82	-1.03	-0.52	-0.67	-0.75	-0.67
EPS Diluted	-3.45	-0.81	-0.79	-0.82	-1.03	-0.52	-0.67	-0.75	-0.67
Weighted Average Basic Shares	111.08M	111.08M	110.07M	95.09M	84.16M	83.88M	83.56M	78.41M	72.78M
Weighted Average Diluted Shares	111.08M	111.08M	110.07M	95.09M	84.16M	83.88M	83.56M	78.41M	72.78M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	11/30/2025	11/30/2024	11/30/2023	11/30/2022	11/30/2021	11/30/2020	11/30/2019	11/30/2018
Revenue	83.98M	54.55M	76.99M	38.63M	29.75M	17.82M	31.11M	37.45M
Cost of Goods Sold	18.86M	221.63M	189.15M	184.50M	116.43M	66.49M	45.02M	40.51M
Gross Profit	65.12M	-167.08M	-112.16M	-145.87M	-86.68M	-48.67M	-13.91M	-3.06M
Gross Profit Margin	77.5%	-306.3%	-145.7%	-377.6%	-291.4%	-273.1%	-44.7%	-8.2%
Total Operating Expenses	350.79M	45.94M	42.90M	38.00M	31.20M	16.31M	8.33M	6.67M
Research & Development	308.16M	221.63M	189.15M	184.50M	116.43M	66.49M	45.02M	40.51M
Selling, General & Administrative	52.74M	45.94M	42.90M	38.00M	31.20M	16.31M	8.33M	6.67M
Operating Income (EBIT)	-285.67M	-213.03M	-155.06M	-183.87M	-117.89M	-64.98M	-22.24M	-9.74M
Operating Margin	-340.2%	-390.5%	-201.4%	-476.0%	-396.3%	-364.7%	-71.5%	-26.0%
Income Before Tax (EBT)	-263.70M	-193.30M	-143.95M	-180.36M	-117.06M	-63.78M	-21.46M	-8.92M
Interest Income	21.97M	19.73M	11.12M	3.51M	823K	1.21M	776K	818K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	21.97M	19.73M	11.12M	3.51M	823K	1.21M	776K	818K
Net Income	-264.46M	-193.57M	-143.95M	-180.36M	-117.19M	-43.24M	-21.70M	-9.43M
Income Tax Expense	760K	270K	0.00	0.00	131K	-20.54M	239K	507K
Net Profit Margin	-314.9%	-354.9%	-187.0%	-466.9%	-393.9%	-242.7%	-69.7%	-25.2%
EBITDA	-266.81M	-205.01M	-148.93M	-179.72M	-115.90M	-62.80M	-19.88M	-6.75M
EBITDA Margin	-317.7%	-375.8%	-193.4%	-465.3%	-389.6%	-352.4%	-63.9%	-18.0%
Depreciation & Amortization	18.86M	8.02M	6.13M	4.15M	1.99M	2.18M	2.35M	2.99M
EPS Basic	-3.05	-2.88	-2.65	-3.71	-2.73	-2.76	-0.56	-0.59
EPS Diluted	-3.05	-2.88	-2.65	-3.71	-2.73	-2.76	-0.56	-0.59
Weighted Average Basic Shares	86.67M	67.12M	54.34M	48.61M	42.90M	15.67M	38.85M	16.11M
Weighted Average Diluted Shares	86.67M	67.12M	54.34M	48.61M	42.90M	15.67M	38.85M	16.11M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.